Literature DB >> 11161840

Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk.

H Jernström1, W Chu, D Vesprini, Y Tao, N Majeed, C Deal, M Pollak, S A Narod.   

Abstract

The oral contraceptive pill is associated with a modest increase in the risk of early-onset breast cancer in the general population, but it is possible that the risk is higher in certain subgroups of women. The relative risk of breast cancer associated with oral contraceptive use has been reported to be higher for African-American women than for white women. African-American women also have a higher incidence of premenopausal breast cancer than white women. Circulating levels of insulin-like growth factor-1 (IGF-I) vary between ethnic groups and are positively associated with the risk of premenopausal breast cancer. In general, the plasma level of IGF-I is lower in women who take oral contraceptives than in women who do not. In an attempt to explain the observed ethnic difference in IGF-I levels with oral contraceptive use, we sought to identify polymorphic variants of genes that are associated with IGF-I levels and estrogen metabolism. We measured IGF-I and IGFBP-3 plasma levels in 503 nulligravid women between the ages of 17 and 35. All women filled out a questionnaire that included information about ethnic background and oral contraceptive use. Samples of DNA were used to genotype the women for known polymorphic variants in the IGF1, AIB1, and CYP3A4 genes. Black women had significantly higher mean IGF-I levels than white women (330 ng/ml versus 284 ng/ml; P = 0.001, adjusted for age and oral contraceptive use). IGF-I levels were significantly suppressed by oral contraceptives in white women (301 ng/ml versus 267 ng/ml; P = 0.0003), but not in black women. Among oral contraceptive users, the IGF-I level was positively associated with the absence of the IGF1 19-repeat allele (338 ng/ml versus 265 ng/ml; P = 0.00007), with the presence of the CYP3A4 variant allele (320 ng/ml versus 269 ng/ml; P = 0.01), and with the presence of the AIB1 26-repeat allele (291 ng/ml versus 271; P = 0.08). After adjusting for genotypes, ethnic group was no longer a significant predictor of the IGF-I level. IGF-I levels are higher among black than white women. Polymorphic variants in the CYP3A4, IGF1, and AIB1 genes are associated with increases in the plasma levels of IGF-I among oral contraceptive users and the variant alleles are much more common in black women than in white women. The high incidence of premenopausal breast cancer among black women may be mediated through genetic modifiers of circulating levels of IGF-I. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161840     DOI: 10.1006/mgme.2000.3130

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  30 in total

1.  Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent.

Authors:  Chad P Garner; Yuan C Ding; Esther M John; Sue A Ingles; Olufunmilayo I Olopade; Dezheng Huo; Clement Adebamowo; Temidayo Ogundiran; Susan L Neuhausen
Journal:  Hum Genet       Date:  2008-01-22       Impact factor: 4.132

2.  Bioavailable insulin-like growth factor-I as mediator of racial disparity in obesity-relevant breast and colorectal cancer risk among postmenopausal women.

Authors:  Su Yon Jung; Wendy E Barrington; Dorothy S Lane; Chu Chen; Rowan Chlebowski; Giselle Corbie-Smith; Lifang Hou; Zuo-Feng Zhang; Min-So Paek; Carolyn J Crandall
Journal:  Menopause       Date:  2017-03       Impact factor: 2.953

3.  Exogenous estrogen as mediator of racial differences in bioactive insulin-like growth factor-I levels among postmenopausal women.

Authors:  Su Yon Jung; Mara Z Vitolins; Electra D Paskett; Shine Chang
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-09-18       Impact factor: 6.053

4.  Influence of promoter region variants of insulin-like growth factor pathway genes on the strength-training response of muscle phenotypes in older adults.

Authors:  Brian D Hand; Matthew C Kostek; Robert E Ferrell; Matthew J Delmonico; Larry W Douglass; Stephen M Roth; James M Hagberg; Ben F Hurley
Journal:  J Appl Physiol (1985)       Date:  2007-08-30

5.  Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults.

Authors:  David Berrigan; Nancy Potischman; Kevin W Dodd; Stephen D Hursting; Jackie Lavigne; J Carl Barrett; Rachel Ballard-Barbash
Journal:  Growth Horm IGF Res       Date:  2008-09-21       Impact factor: 2.372

6.  A microsatellite polymorphism in IGF1 gene promoter and longevity in a Han Chinese population.

Authors:  Liang Xie; Yuan-Ying Gong; Shi-Gang Lian; Juan Yang; Shou-Jun Gao; Liang-You Xu; Ya-Ping Zhang
Journal:  BMC Res Notes       Date:  2010-03-03

7.  Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels.

Authors:  Rong Yuan; Shirng-Wern Tsaih; Stefka B Petkova; Caralina Marin de Evsikova; Shuqin Xing; Michael A Marion; Molly A Bogue; Kevin D Mills; Luanne L Peters; Carol J Bult; Clifford J Rosen; John P Sundberg; David E Harrison; Gary A Churchill; Beverly Paigen
Journal:  Aging Cell       Date:  2009-04-09       Impact factor: 9.304

8.  Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families.

Authors:  Maria Henningson; Erika Bågeman; Therese Sandberg; Ake Borg; Håkan Olsson; Helena Jernström
Journal:  Fam Cancer       Date:  2007-05-05       Impact factor: 2.375

9.  Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3.

Authors:  Jay H Fowke; Charles E Matthews; Herbert Yu; Qiuyin Cai; Sarah Cohen; Maciej S Buchowski; Wei Zheng; William J Blot
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

10.  Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites.

Authors:  Cathrine Hoyo; Janet Grubber; Wendy Demark-Wahnefried; Jeffrey R Marks; Stephen J Freedland; Amy S Jeffreys; Steven C Grambow; Robert M Wenham; Philip J Walther; Joellen M Schildkraut
Journal:  J Natl Med Assoc       Date:  2007-07       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.